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Abstract 
Review on NOL4L, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
Keywords 
NOL4L; C20orf112; C20orf113; Acute 
lymphoblastic leukemia; Acute myeloid leukemia: 
Breast adenocarcinoma; Skin melanoma; Uterus 
cancer; Bladder cancer. 
Identity 
Other names: LOC140688 
HGNC (Hugo): NOL4L 
Location: 20q11.2 
Local order 
Cen --- PLAGL2, POFUT1, KIF3B, ASXL1, 
NOL4L, NOL4L-DT, C20orf203, COMMD7, 
DNMT3B ---Tel 
Note 
This gene and protein is very poorly known; a very 






8 potential splice forms coding for potential proteins 
with 76 amino acids (aa) to 680 aa. 
Protein 
Note 
Nothing is known concerning the domains of the 
protein, nor it's function. 
Description 
Two coding proteins: NOL4L-010, from: 11 exons; 
transcript length: 6,577 bps translation: 680 amino 
acids; and NOL4L-001, from: 8 exons; transcript 
length: 5,991 bps translation: 436 amino acids. A 
Poly-Asp is found at aa 161 to 169 according to Vega 
(http://vega.archive.ensembl.org/Homo_sapiens/Ge
ne/Summary?db=core;g=OTTHUMG00000032219




Expressed in all tissues; High expression in the 
testis, and, to a lesser extend, in the small 
intestine,other digestive organs, brain and bone 
marrow. NOL4L orthologs are present in most 
vertebrates and are well conserved. 
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In zebrafish embryos, Znol4lb (the zebrafish nol4l 
with the highest identity with human NOL4L) 
mRNA is localized to the intermediate mesoderm. It 
is expressed in the central nervous system, 
pronephros, the gut and, at low levels, in the 
hematopoietic cells (Borah et al. 2016). 
Localisation 
Mainly localized to the nucleoplasm. 
Function 
Acccording to BioGRID 
(https://thebiogrid.org/12665), interacts with:  
CTBP1 (C-terminal binding protein 1), corepressor 
targeting various transcription regulators.  
TEX9 (testis expressed 9).  
SRPK1 (SRSF protein kinase 1), involved in the 
regulation of splicing via phosphorylation of splicing 
factors.  
CTBP2 (C-terminal binding protein 2), corepressor 
targeting various transcription regulators.  
SKA3 (spindle and kinetochore associated complex 
subunit 3), component of a microtubule-binding 
complex essential for chromosome segregation.  
TRIM25 (tripartite motif containing 25), ubiquitin 
E3 ligase.  
MIR206 (microRNA 206). 
Implicated in 
Top note 
 Expression level according to Entrez 
(https://www.ncbi.nlm.nih.gov/gene/140688) and 
The Human Protein Atlas 
(http://www.proteinatlas.org/ENSG00000197183-
NOL4L/pathology):  
High expression of NOL4L is an unfavourable 
prognostic factor in endometrial cancer. 
High expression of NOL4L is a favourable 
prognostic factor in urothelial cancer.  
Expression level of NOL4L has no prognostic 
significance in: Glioma, Thyroid cancer, Lung 
cancer, Liver cancer, Pancreatic cancer, Head and 
neck cancer, Stomach cancer, Colorectal cancer, 
Renal cancer, Prostate cancer, Testis cancer, Breast 
cancer, Cervical cancer, Ovarian cancer, Melanoma. 
 Main translocations:  (detailed herein below)  
- dic(9;20)(p13;q11) PAX5/NOL4L. 
- t(20;21)(q11;q22) RUNX1/NOL4L. 




- fusion/translocation t(7;20)(p22;q11) 
ACTB/NOL4L in triple-negative (TN) 
adenocarcinoma. The triple-negative breast cancer 
subtype is the most aggressive form of invasive 
breast adenocarcinoma (Asmann et al. 2012).  
- fusion/translocation t(17;20)(q22;q11) 
MMD/NOL4L in breast adenocarcinoma (Yoshihara 
et al. 2015).  
- fusion 20q11-20q11 NOL4L/ COMMD7 in breast 
adenocarcinoma (Yoshihara et al. 2015).  
- fusion 20q11-20q11 NOL4L/ EFCAB8 in 
malignant melanoma of the skin (Hu et al., 2018). 
- fusion 20q11-20q11 PDRG1/NOL4L in malignant 
epithelial tumor of the uterus corpus (Hu et al., 
2018). 
Pediatric acute lymphoblastic 
leukemia (ALL) 
Note 
5 cases of dic(9;20) (p13;q11) PAX5/NOL4L  
available to date (Nebral et al., 2007; An et al., 2008; 
Kawamata et al., 2008; Kawamata et al. 2012). 
Hybrid/Mutated gene 
In one case, exon 5 of PAX5 was fused to exon 8 of 
NOL4L, and in four cases, exon 8 of PAX5 was 
fused to exon 3 of NOL4L, producing two proteins, 
a short (PAX5/C20ORF112S) and long 
(PAX5/C20ORF112L) form, localizing in the 
nucleus, and/or in the cytoplasm and the nucleus 
(Kawamata et al., 2008). 
Oncogenesis 
Four downstream target genes of PAX5 ( ATP1B1, 
BLK, SEPT2 and TCF7L2) were down-regulated by 
induction of PAX5/NOL4L. Loss of the C-terminal 
end of PAX5 may play role in generation of a 
dominant negative form of mutated PAX5 
(Kawamata et al., 2008). 
Acute myeloid leukemia (AML) 
Note 
A 62-year-old man was diagnosed with AML with 
maturation (M2- AML), and presented with a 
t(20;21)(q11.2;q22.1) RUNX1/NOL4L 
accompanied with monosomy 7 (Guastadisegni et al. 
2010). 
Hybrid/Mutated gene 
RUNX1 exon 6 was fused to NOL4L exon 8. 
Oncogenesis 
Wild-type NOL4L was expressed at low levels in 
AML and normal bone marrow, whereas the 
RUNX1/NOL4L was expressed at high levels 
(Guastadisegni et al. 2010). 
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